A Different Approach to Weight Loss
The global obesity epidemic has fueled explosive demand for pharmacological weight-loss solutions, with GLP-1 receptor agonists dominating headlines. But these injectable drugs come with side effects, high costs, and supply constraints that leave many patients without options. Researchers at Nanyang Technological University in Singapore have now developed an entirely different kind of intervention: an orally administered compound derived from natural gut chemistry that reduces fat absorption in the intestines without affecting glucose uptake or causing systemic toxicity.
Published in Pharmacological Research, the study validates the compounds in animal models and outlines a commercialization pathway that could bring them to consumers first as a supplement and eventually as a regulated therapeutic.
How the Compound Works
The NTU team, led by Associate Professor Andrew Tan and Professor Tan Choon Hong, designed molecules that operate through two complementary mechanisms. First, the compounds block a receptor on intestinal epithelial cells that facilitates dietary fat absorption. By occupying this receptor, the molecules reduce the amount of fat that passes from the gut lumen into the bloodstream.
Second, the compounds promote the growth of beneficial gut bacteria that produce short-chain fatty acids (SCFAs). SCFAs are known to strengthen the gut barrier, modulate appetite signaling, and improve metabolic health. By encouraging SCFA-producing microbes, the treatment may deliver benefits beyond simple fat blocking.
Crucially, the compounds remain localized within the gut and do not enter systemic circulation in significant quantities. This gut-restricted distribution is a deliberate design choice: it minimizes the risk of off-target effects in other organs, a concern that has dogged many previous weight-loss drugs.
Animal Model Results
In mice fed a high-fat diet, oral administration of the compounds led to measurably less weight gain and reduced fat accumulation in the liver compared to untreated controls. The treated mice showed no signs of toxicity under laboratory conditions, and importantly, their absorption of glucose and other sugars was unaffected, meaning the compounds selectively target fat without disrupting carbohydrate metabolism.
